Brent Pfeiffenberger
Förmögenhet: 7 M $ per 2026-08-31
Förmögenhet: 7 M $ per 2026-08-31
Brent Pfeiffenberger is Chairman, President & Chief Executive Officer at Century Therapeutics, Inc. since 2025 and Independent Director at Corbus Pharmaceuticals Holdings, Inc. since 2026.
Former roles include Chief Operating Officer at Neogene Therapeutics, Inc. from 2021 to 2023 and Director at Medicines Australia.
Education includes an MBA from The Wharton School of the University of Pennsylvania and a doctorate from Duquesne University.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
| 2026-09-11 | 3 633 839 ( 2,01 % ) | 7 M $ | 2026-08-31 |
| Företag | Position | Start |
|---|---|---|
| CENTURY THERAPEUTICS, INC. | Verkställande Direktör | 2023-12-04 |
| CORBUS PHARMACEUTICALS HOLDINGS, INC. | Direktör/Styrelseledamot | 2026-05-13 |
| Företag | Position | Slut |
|---|---|---|
Neogene Therapeutics, Inc.
Neogene Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company that provides TCR therapies targeting neo-antigens in solid cancers | Verksamhetschef | 2023-12-01 |
Medicines Australia
Medicines Australia Pharmaceuticals: MajorHealth Technology Manufactures and supplies medicines and vaccines | Direktör/Styrelseledamot | - |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 5 |
|---|---|
Medicines Australia
Medicines Australia Pharmaceuticals: MajorHealth Technology Manufactures and supplies medicines and vaccines | Health Technology |
The Wharton School of the University of Pennsylvania
The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases | Health Technology |
Neogene Therapeutics, Inc.
Neogene Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company that provides TCR therapies targeting neo-antigens in solid cancers | Health Technology |
Century Therapeutics, Inc.
Century Therapeutics, Inc. BiotechnologyHealth Technology Develops novel allogeneic living drugs for oncology that overcome the limitations of first-generation cell therapies | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån